3rd Circ. Says Amgen Can Proceed With Subpoena In IP Suit

The Third Circuit on Thursday sided with biotechnology company Amgen Inc. in its efforts to subpoena a competitor that it accused of patent infringement, reasoning that the panel lacked jurisdiction to...

Already a subscriber? Click here to view full article